Uncategorized

ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer

Published

2 weeks ago

on

Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version